Johan Vansteenkiste

Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia

Jean-Luc Canon, Johan Vansteenkiste, G. Bodoky et al. · JNCI Journal of the National Cancer Institute · 2006 · 104 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: Disease Progression and Survival Analysis From Four Randomized, Double-Blind, Placebo-Controlled Trials

Michael Hedenus, Johan Vansteenkiste, Dusan Kotasek et al. · Journal of Clinical Oncology · 2005 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline

Giuseppe Rossi, Robert Pirker, Johan Vansteenkiste et al. · Supportive Care in Cancer · 2004 · 33 citations

Medicine, Oncology, Pharmacology +8

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

Johan Vansteenkiste, Michael Hedenus, Pere Gascón et al. · BMC Cancer · 2009 · 22 citations · Full text

Medicine, Hematology, Pharmacology +14

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent

Robert Pirker, Melissa Pirolli, Jane Quigley et al. · Supportive Care in Cancer · 2012 · 16 citations · Full text

Medicine, Hematology, Oncology +9